customer service
Reader Domain Proteins







SARS-CoV-2 Related Assays


To support the drug discovery community in the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication including:

  • 1. Biophysical Binding Assays to Block S Protein and ACE2 Interaction
  • 2. Enzymatic Inhibition Assays for COVID related proteases
Protease Assays
Reaction Biology developed assays to investigate the inhibition of proteases that are essential for the replication cycle of SARS-CoV-2, the novel coronavirus responsible for COVID-19.

These assays are being offered to enable timely discovery and development of COVID-19 therapeutics:
SPR Assays
Two assays were developed at Reaction Biology to investigate the binding interaction between the receptor binding domain of the viral S protein and ACE2. These assays can be used to measure:

  • a.) the direct binding of potential therapeutics to the S protein receptor binding domain or ACE2 to determine the kinetics of the interaction or
  • b.) whether the test molecule(s) disrupt the S protein /ACE2 interaction.

  • See more data here.














With the largest functional kinase activity assay panel in the industry, RBC provides kinase, epigenetic, and other profiling services to over 750 companies worldwide. RBC specializes in custom assay conditions, high quality reproducible data, and outstanding service.

Reaction Biology Corp. 1 Great Valley Parkway, Suite 2 Malvern, PA 19355 1-877-347-2368 or 610-722-0247
Sales@reactionbiology.com
Reaction Biology Corp. © 2016 all rights reserved.